OClawVPS.com
Dyal Capital Partners
Edit

Dyal Capital Partners

https://www.blueowl.com
Last activity: 08.04.2026
Active
Blue Owl is a market leader in direct lending & capital solutions for the alternatives industry. We offer wealth clients distinctive service.
Portfolio
9
Mentions
259
Employees: 11-50

Portfolio 9

DateNameWebsiteTotal RaisedLocation
01.04.2026Ambrosia B...ambrosiabiosciences.com$141MUnited Sta...
25.02.2026Allica Ban...allica.bank$2.13BUnited Kin...
20.02.2026Vestwellvestwell.com$622.5MUnited Sta...
10.02.2026Deep Fissi...deepfission.com$114MUnited Sta...
13.01.2026Mirador Th...miradortx.com$250MUnited Sta...
12.12.2025Finance of...financeofamerica.com$2.55BUnited Sta...
05.12.2025Coremontcoremont.com$40MUnited Sta...
24.10.2025Crusoe Ene...crusoeenergy.com$2.22BUnited Sta...
26.09.2025Nscalenscale.com$3.26BU.K.

Mentions in press and media 259

DateTitleDescription
08.04.2026Moody’s ухудшило прогноз для $36-миллиардного фонда Blue Owl: тревожный сигнал для private creditMoody’s Ratings изменило прогноз по Blue Owl Credit Income Corp (OCIC), одному из крупнейших фондов Blue Owl объемом около $36 млрд, со «stable» на «negative». Причиной стали заявки на выкуп в первом квартале 2026 года, которые, по оценке а...
07.04.2026Goldman Sachs flagship private credit fund bucks industry sell-offGoldman Sachs’ flagship private credit fund has said investors looked to pull less than five per cent of their holdings in the first three months of this year, dodging an industry-wide redemptions wave that has forced some rivals to gate th...
07.04.2026Private credit firm exposed after cosmetics retailer plunges into administrationA private credit firm has been forced to write down the value of one of its portfolio companies after online retailer Give Me Cosmetics was placed into administration. London-based Beechbrook capital, which offers finance to lower mid-marke...
03.04.2026Ambrosia Biosciences Fuels Next-Gen Oral Metabolic Drug DevelopmentAmbrosia Biosciences secured a monumental $100 million Series B funding. This capital injection immediately accelerates their oral small molecule GLP-1 candidate into pivotal clinical trials. It also vigorously advances their broader pipeli...
03.04.2026Private Credit Market Jitters: Blue Owl Caps Billions in Redemptions Amid AI FearsBlue Owl confronted a surge in private credit redemptions. Investors sought to withdraw billions from its flagship OCIC and tech-focused OTIC funds. Requests reached 21.9% and 40.7% respectively. The firm implemented a strict 5% withdrawal ...
02.04.2026Blue Owl caps private credit funds redemptions at 5% after steep request levelsBlue Owl revealed higher-than-usual redemption requests in its OCIC and OTIC private credit funds. Blue Owl attributed the higher-than-usual requests to “heightened market concerns around AI-related disruption to software companies.” In bot...
02.04.2026Blue Owl caps private credit redemptions after investors try to pull $5.4bnInvestors in Blue Owl’s multi-billion dollar private credit fund have asked to withdraw around a fifth of their money in another dramatic escalation of jitters across Wall Street and the financial ecosystem. The asset manager’s flagship $36...
01.04.2026Blue Owl Capital: $2.9 Billion Raised For Asset Special Opportunities Fund IXBlue Owl Capital has announced the final close of its Asset Special Opportunities Fund IX, raising approximately $2.9 billion in total capital commitments and exceeding its initial $2.5 billion target. The fund, known as ASOF IX, is a diver...
01.04.2026Ambrosia Biosciences: $100 Million Raised For Cardiometabolic Small Molecule Pipeline AdvancementAmbrosia Biosciences announced that it has raised $100 million in an oversubscribed Series B financing round to advance its pipeline of orally delivered small molecule therapies targeting cardiometabolic diseases. The financing was co-led b...
31.03.2026Ambrosia Biosciences Raises $100M in Series B FundingAmbrosia Biosciences, a Boulder, CO-based drug discovery company, raised $100M in Series B funding. The round was led by Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital, with participation from existing investors BVF Partn...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In